PIQ Pharma

PIQ Pharma is a clinical-stage biotechnology company based in Shanghai, China, focused on the development of targeted oncology therapies. Incubated by Pivotal bioVenture Partners China, the company centers its efforts on the development and commercialization of PIQ-001, a highly selective small molecule inhibitor of PI3Kα. PIQ-001 was licensed from Novartis and is currently being evaluated in clinical trials for patients with advanced solid tumors harboring PIK3CA mutations. The company aims to address significant unmet medical needs in the Greater China market by leveraging its specialized clinical development expertise in the PI3K/AKT/mTOR pathway.